Reason for request
Inclusion on the list of medicines refundable by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of CAPRELSA is substantial. |
Clinical Added Value
| minor |
The transparency Commission considers that CAPRELSA provides a minor improvement in the actual benefit (IAB level IV) in the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. |
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
Z3hwe4nTeJ2b5G8w
